d-Dimer elevation and adverse outcomes
View/ Open
Author
Popma, Christopher J.
Cohen, Ander
Chi, Gerald
Zacarkim, Marcelo Rodrigues
Romero, Gonzalo
Hull, Russell
Hernandez, Adrian
Mentz, Robert
Harrington, Robert
Lip, Gregory
Peacock, Frank
Welker, James
Martin-Loeches, Ignacio
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1007/s11239-014-1101-6Metadata
Show full item recordCitation
Halaby, R., C. J. Popma, A. Cohen, G. Chi, M. R. Zacarkim, G. Romero, S. Z. Goldhaber, et al. 2014. “d-Dimer elevation and adverse outcomes.” Journal of Thrombosis and Thrombolysis 39 (1): 55-59. doi:10.1007/s11239-014-1101-6. http://dx.doi.org/10.1007/s11239-014-1101-6.Abstract
d-Dimer is a biomarker of fibrin formation and degradation. While a d-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated d-dimer with adverse outcomes has received far less emphasis. An elevated d-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated d-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the d-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300425/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890728
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)